Elicera Therapeutics publishes the annual report for 2022

Elicera Therapeutics publishes the annual report for 2022

Gothenburg, April 17, 2023 – Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells armed with bystander immune activating properties, using the company’s proprietary and commercially available platform iTANK, publishes the annual report for 2022.

Elicera Therapeutics annual report is now available at the webpage https://www.elicera.com.

The Annual General Meeting will be held on May 16th at 3:00 p.m. at the offices of Advokatfirman Delphi (Mäster Samuelsgatan 17 in Stockholm).

For further information please contact:

Jamal El-Mosleh, CEO, Elicera Therapeutics AB

Phone: +46 (0) 703 31 90 51
jamal.elmosleh@elicera.com

Certified Advisor

Erik Penser Bank

The information was submitted for publication distributed through the contact person above at 15:09 CET on April 17, 2023.

About Elicera Therapeutics AB

Elicera Therapeutics AB is a clinical stage cell and gene therapy company that develops next-generation therapies based on oncolytic viruses and CAR T-cells, armed with the company’s proprietary and commercially available platform, iTANK. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T-cells and two oncolytic viruses. The iTANK-platform is used to arm the company's own CAR T-cells, in addition to the oncolytic virus ELC-201, but can also be universally applied to other CAR/TCR T-cell therapies under development. The company’s share (ELIC) is traded on Nasdaq First North Growth Market. For more information, please visit www.elicera.com